Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
3 ASX Stocks Rise Up to 12.6% on Takeover Waiver and Employee Option Updates
Highlights
Three ASX-listed companies posted strong gains on 22 September 2026. One cleared a regulatory step in a major overseas acquisition, while the other two lodged routine filings on option exercises. Here is what each disclosed.
How the shares moved
Telix gains flexibility on ITM share issues
Telix Pharmaceuticals announced on 22 September 2026 that the ASX had granted waivers of Listing Rule 7.3.4 for its planned takeover of Germany's ITM Isotope Technologies Munich. The rule normally requires approved shares to be issued within three months of a shareholder meeting.
The deal involves issuing 105.8 million Telix shares, worth about US$1.25 billion, as part of the US$1.65 billion upfront price, with up to US$700 million more tied to ITM-11 approvals and sales. The waivers let Telix issue those upfront shares up to 12 months after shareholders approve them at an extraordinary general meeting expected in November 2026. Any milestone shares can follow within three months of each FDA approval, or within four months of Telix's 2030 accounts for the sales milestone.
Electro Optic Systems settles employee options
Electro Optic Systems lodged an Appendix 3G on 22 September 2026, confirming that 26,000 employee options were exercised on 21 September. Of these, 20,000 had a AU$0.50 strike price and 6,000 a AU$1.70 strike. The holders received 23,912 existing shares rather than newly issued stock, leaving the total at 221,702,162 shares.
Sunrise Energy Metals quotes new shares
Sunrise Energy Metals applied on 21 September 2026 to quote 6,253 shares issued after holders exercised options from its share purchase plan at AU$0.40 each, raising about AU$2,501. Ordinary shares on issue now total 169,492,198.
The bigger picture
None of these filings explains the size of the moves. The Telix waiver is procedural, and the option exercises at Sunrise and EOS are too small to shift valuations. Telix's rebound is notable, though: at AU$16.84, the stock is back above the AU$16.65 price used to set the ITM sellers' shares, easing one of the market's main concerns from the day before.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au